| May 1998 | Was co-founded by Kyowa Hakko Kogyo Co., Ltd. and Dr. Matsumoto with the aim of “supporting the speedy development of drugs required by patients”. |
| Aug 2003 | Entered into a co-development agreement with PsychoGenics, Inc. for eltoprazine. |
| May 2004 | Entered into an agreement with bene pharmaChem GmbH & Co. KG for co-development of Pentosan PolySulfate (PPS). |
| Jan 2007 | Started Phase I clinical trial of PPS in Japan |
| Mar 2009 | Started pharmacokinetic study of eltoprazine in Japanese subjects in the U.S. |
| Apr 2010 | Started Phase II clinical trial of PPS for OsteoArthritis (OA) in Japan. |
| Sep 2010 | Entered into a license agreement with Chong Kun Dang Pharmaceutical Corp. for PPS in Korea |
| Jun 2011 | Was selected as a developer of betaine, a development support product for the Ministry of Health, Labour and Welfare’s unapproved drug development support program |
| Sep 2012 | Entered into a license agreement with Orphan Europe SARL to acquire exclusive rights to develop and to commercialize betaine in Japan. |
| Mar 2012 | Received orphan drug designation for betaine from the Ministry of Health, Labour and Welfare |
| Mar 2012 | Started Phase III clinical trial of betaine in Japan |
| Mar 2013 | Applied to domestic manufacturing and marketing approval of Cystadan® bulk powder (generic name: betaine) for the treatment of homocystinuria |
| Apr 2013 | Obtained first-class marketing authorization |
| Jan 2014 | Was approved for manufacturing and marketing of Cystadan® bulk powder |
| May 2014 | Commercially launched Cystadan® bulk powder |
| Oct 2014 | Started Phase II clinical trials of PPS for HTLV-1 Associated Myelopathy (HAM) |
| Sep 2015 | Started Pediatric safety study of PPS for MucoPolySaccharidosis (MPS) |
| Dec 2017 | Started Phase II clinical trial of PPS for MPS and Mucolipidosis |
| Apr 2019 | Signed a license agreement with Icahn School of Medicine at Mount Sinai for PPS (indication: MPS) |
| May 2020 | Started domestic Phase III clinical trial of Cholic Acid |
| Aug 2020 | Received orphan drug designation cholic acid from the Ministry of Health, Labour and Welfare |